Trial · NCT01494987
Adverse events24
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 24
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hyperglycemia | Metabolism and nutrition disorders | Placebo+Glimepiride | 32 | 216 | |
| other | Hyperglycemia | Metabolism and nutrition disorders | Ranolazine+Glimepiride | 21 | 215 | |
| other | Hypoglycaemia | Metabolism and nutrition disorders | Placebo+Glimepiride | 10 | 216 | |
| other | Hypoglycaemia | Metabolism and nutrition disorders | Ranolazine+Glimepiride | 13 | 215 | |
| other | Nausea | Gastrointestinal disorders | Placebo+Glimepiride | 7 | 216 | |
| other | Nausea | Gastrointestinal disorders | Ranolazine+Glimepiride | 11 | 215 | |
| serious | Acute myocardial infarction | Cardiac disorders | Placebo+Glimepiride | 1 | 216 | |
| serious | Acute myocardial infarction | Cardiac disorders | Ranolazine+Glimepiride | 0 | 215 | |
| serious | Myocardial ischaemia | Cardiac disorders | Placebo+Glimepiride | 0 | 216 | |
| serious | Myocardial ischaemia | Cardiac disorders | Ranolazine+Glimepiride | 1 | 215 | |
| serious | Ventricular extrasystoles | Cardiac disorders | Placebo+Glimepiride | 1 | 216 | |
| serious | Ventricular extrasystoles | Cardiac disorders | Ranolazine+Glimepiride | 0 | 215 | |
| serious | Eye haemorrhage | Eye disorders | Placebo+Glimepiride | 0 | 216 | |
| serious | Eye haemorrhage | Eye disorders | Ranolazine+Glimepiride | 1 | 215 | |
| serious | Retinal vein thrombosis | Eye disorders | Placebo+Glimepiride | 0 | 216 | |
| serious | Retinal vein thrombosis | Eye disorders | Ranolazine+Glimepiride | 1 | 215 | |
| serious | Back pain | Musculoskeletal and connective tissue disorders | Placebo+Glimepiride | 0 | 216 | |
| serious | Back pain | Musculoskeletal and connective tissue disorders | Ranolazine+Glimepiride | 1 | 215 | |
| serious | Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo+Glimepiride | 0 | 216 | |
| serious | Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Ranolazine+Glimepiride | 1 | 215 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01494987/events